Tirzepatide Price Guide: How Much Does It Cost Without Insurance?

What Drives the Cost of Tirzepatide

Tirzepatide is a relatively new dual GIP/GLP-1 receptor agonist approved by the FDA under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). Because both formulations are still under patent protection, there are no generic versions available, and the manufacturer Eli Lilly sets the list price. The tirzepatide price reflects the high cost of biologic drug development, specialized manufacturing, and the pen-injector delivery system required for subcutaneous administration. Understanding these cost drivers helps you navigate your options before paying out of pocket.

Retail List Price for Mounjaro and Zepbound

Without insurance, the cash price for a four-week supply of tirzepatide varies by brand and dose. Mounjaro, prescribed for type 2 diabetes, carries a manufacturer list price of roughly $1,060 to $1,070 per month regardless of dose level. Zepbound, the obesity indication, launched at a similar price point, ranging from approximately $1,060 for the 2.5 mg and 5 mg starter doses up to about $1,086 per month for the higher maintenance doses of 10 mg, 12.5 mg, and 15 mg. These figures represent the Wholesale Acquisition Cost and do not include pharmacy dispensing fees, which typically add $5 to $30 depending on the pharmacy.

Prices at major retail chains such as CVS, Walgreens, and Walmart tend to track the list price closely in the absence of a coupon or discount program. Mail-order pharmacies and warehouse club pharmacies like Costco sometimes offer slightly lower cash prices, so it is worth calling ahead to compare before filling your prescription.

Eli Lilly Savings Programs and Direct Pricing

Eli Lilly offers two programs that can substantially reduce the tirzepatide price for eligible patients. The Mounjaro Savings Card and the Zepbound Savings Card are available to commercially insured patients who still face high out-of-pocket costs, reducing the monthly copay to as little as $25 for a 30-day supply. These savings cards are not available to patients on Medicare, Medicaid, or other federal programs.

For uninsured patients, Eli Lilly launched Zepbound vials through its LillyDirect pharmacy platform in late 2023. Single-dose vials sold through LillyDirect are priced at $399 per month for the two lower doses and $549 per month for the higher doses, making them meaningfully more affordable than the auto-injector pen option. Patients must have a valid prescription and use a compatible self-injection syringe, but this pathway represents one of the most significant cost reductions available without insurance involvement.

Compounded Tirzepatide: Lower Cost, Real Risks

During the FDA drug shortage period for tirzepatide, many 503A and 503B compounding pharmacies began producing tirzepatide for a fraction of the brand-name price, often in the range of $150 to $400 per month. Some telehealth platforms facilitated access to these compounded versions. However, the FDA declared tirzepatide shortage periods resolved and issued guidance that compounding pharmacies must stop producing copies of the drug once it is no longer on the shortage list. Compounded tirzepatide carries additional risks including inconsistent potency, sterility concerns, and the absence of the clinical trial safety data that applies to the branded product. Anyone considering this route should verify the pharmacy's 503B accreditation and consult their prescribing physician.

How to Lower Your Out-of-Pocket Cost

If you are paying cash for tirzepatide, several practical strategies can reduce what you spend each month.

• Apply for the manufacturer savings card through Eli Lilly's website if you have commercial insurance with a high deductible or copay.
• Ask your prescriber about LillyDirect vials, which carry the lowest direct cash price for uninsured patients.
• Use a GoodRx or RxSaver coupon at participating pharmacies, which can occasionally bring the retail price down by 10 to 20 percent, though savings vary widely by location.
• Check whether your employer's health plan has a specialty drug carve-out or a patient assistance exception that covers GLP-1 agonists for metabolic indications.
• Explore Eli Lilly's Insulin Value Program or broader patient assistance program if your annual income falls below the eligibility threshold, which is typically around 400 percent of the federal poverty level.

Insurance Coverage and What to Expect

Coverage for tirzepatide varies significantly by insurance plan. Most commercial plans cover Mounjaro when prescribed for type 2 diabetes, but coverage for Zepbound as an obesity treatment is less consistent. As of 2025, Medicare Part D covers Zepbound for qualifying patients due to legislative changes under the Inflation Reduction Act's expanded obesity drug provisions, but individual plan formularies still determine your specific tier and cost-sharing amount. Prior authorization is nearly universal for both brands, requiring documented diagnosis, BMI thresholds, and often evidence of a comorbid condition such as hypertension or sleep apnea.

When insurance does cover tirzepatide, the typical patient cost falls between $25 and $150 per month depending on the plan tier. Specialty tier placement, which is common, can push copays to $100 or more even with coverage. Appealing a denial on medical necessity grounds is often worthwhile, particularly when your prescriber submits supporting clinical documentation. Understanding the full tirzepatide price landscape, from list price to savings programs to insurance negotiation, puts you in the best position to access this medication at a cost you can sustain long term.